Table 2 Treatment results
Response by RECIST criteria to nCTX: | n = |
|---|---|
   Complete response (CR) | 3 |
   Partial response (PR) | 12 |
   Stable disease (SD) | 31 |
   Progressive disease (PD) | 4 |
Adjuvant treatment: | Â |
   Surgery + RTX + aCTX | 31 |
   Surgery + RTX | 11 |
   Surgery without further adj. treatment | 2 |
   RTX | 4 |
   No definitive surgery | 5 |
Tumor necrosis (Salzer-Kuntschik): | Â |
   Grade 1 (no vital tumor) | 8 |
   Grade 2 (single vital tumor cells) | 4 |
   Grade 3 (vital tumor < 10%) | 4 |
   Grade 4 (vital tumor 10-50%) | 11 |
   Grade 5 (vital tumor >50%) | 16 |
   Grade 6 (completely vital tumor) | 2 |
Radiotherapy | Â |
   Intra-operative RTX | 37 |
   Median dose | 15 Gy (10 - 15 Gy) |
   Adjuvant RTX | 45 |
   Median dose | 45.0 Gy (20 - 66 Gy) |
Therapy failure: | Â |
   Distant metastases: | 12 |
   Pulmonary | 9 |
   Lymph nodes | 3 |
   Other | 1 |
   Local failure | 3 |
   Distant and local failure: | 1 |
Toxicity assessment (≥ CTCAE 3) |  |
   Hematological tox. | 18 |
   Neutropenic fever | 4 |
   Cardiac tox. (any grade) | 2 |
   Ifosfamide-induced encephalopathy | 4 |
   Nausea/Vomiting | 7 |